3种三联疗法治疗幽门螺杆菌感染和消化性溃疡的成本-效果分析

Cost-Effectiveness Analysis of Three Triple Therapies for Helicobacter Pylori and Peptic Ulcer

目的:评价3种三联疗法治疗幽门螺杆菌(Hp)感染和消化性溃疡的成本-效果。方法:将75例胃溃疡和十二指肠溃疡并Hp阳性的患者随机分为A、B、C组,分别服用雷贝拉唑+克拉霉素+呋喃唑酮、奥美拉唑+克拉霉素+呋喃唑酮、泮托拉唑+克拉霉素+呋喃唑酮,观察各组疗效、不良反应,并进行成本-效果分析。结果:A、B、C组的成本分别为2 464.78、1 952.822、020.46元,总有效率分别为96.43%、95.83%、95.65%(P>0.05),成本-效果比分别为2 556.03、2 037.80、2 112.35,A、C组相对于B组的增量成本-效果比分别为85 326.67、—37 577.78。结论:B方案较佳。

OBJECTIVE： To evaluate the cost- effectiveness of 3 triple therapies for helicobacter pylori（Hp） and peptic Ulcer.METHODS： A total of 75 patients with gastroduodenal ulcer associated with Hp were randomized to Group A （rabeprazole ＋ clarithromycin＋ furazolidone）, Group B（omeprazole＋ clarithromycin＋ furazolidone） and Group C（pantoprazole ＋ clarithromycin ＋ furazolidone） .The main outcome measures were curative effects and ADR.A cost- effectiveness analysis of the 3 groups was conducted as well.RESULTS： The costs for Group A, B and C were 2 464.78 yuan, 1 952.82yuan and 2 020.46yuan, respectively（P 〉 0.05） ; the total effective rates were 96.43 %, 95.83% and 95.65 %, respectively; the incremental cost - effectiveness ratios of Group A and Group C as against Group B were 85 326.67 and -37 577.78, respectively. CONCLUSION：Regime B was preferable among the 3 therapeutic regimes.